These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 19085649)

  • 21. Diagnosis and treatment of von Willebrand disease.
    Cox Gill J
    Hematol Oncol Clin North Am; 2004 Dec; 18(6):1277-99, viii. PubMed ID: 15511616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinguishing between type 2B and pseudo-von Willebrand disease and its clinical importance.
    Enayat MS; Guilliatt AM; Lester W; Wilde JT; Williams MD; Hill FG
    Br J Haematol; 2006 Jun; 133(6):664-6. PubMed ID: 16704444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
    Jacquemin M
    Acta Haematol; 2009; 121(2-3):102-5. PubMed ID: 19506355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic defects in von Willebrand disease type 3 in Indian and Greek patients.
    Gupta PK; Saxena R; Adamtziki E; Budde U; Oyen F; Obser T; Schneppenheim R
    Blood Cells Mol Dis; 2008; 41(2):219-22. PubMed ID: 18485763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using genetic diagnostics in hemophilia and von Willebrand disease.
    Swystun LL; James P
    Hematology Am Soc Hematol Educ Program; 2015; 2015():152-9. PubMed ID: 26637715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re-evaluation of three Israeli families initially diagnosed with type 1 von Willebrand disease in light of the ISTH update on von Willebrand factor pathophysiology and classification.
    Hashemi Soteh SM; Anson J; Inbal A; Peake IR; Goodeve AC
    Haemophilia; 2008 May; 14(3):621-4. PubMed ID: 18384353
    [No Abstract]   [Full Text] [Related]  

  • 27. Genetics of type 1 von Willebrand disease.
    Goodeve A
    Curr Opin Hematol; 2007 Sep; 14(5):444-9. PubMed ID: 17934350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Von Willebrand's disease--gene, molecule, clinical findings, treatment].
    Brosstad F
    Tidsskr Nor Laegeforen; 1993 Sep; 113(23):2894-8. PubMed ID: 8236189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene conversions are a common cause of von Willebrand disease.
    Gupta PK; Adamtziki E; Budde U; Jaiprakash M; Kumar H; Harbeck-Seu A; Kannan M; Oyen F; Obser T; Wedekind I; Saxena R; Schneppenheim R
    Br J Haematol; 2005 Sep; 130(5):752-8. PubMed ID: 16115133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic mutations in von Willebrand disease identified by DHPLC and DNA sequence analysis.
    Kakela JK; Friedman KD; Haberichter SL; Buchholz NP; Christopherson PA; Kroner PA; Gill JC; Montgomery RR; Bellissimo DB
    Mol Genet Metab; 2006 Mar; 87(3):262-71. PubMed ID: 16321553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. von Willebrand disease update: diagnostic and treatment dilemmas.
    Bolton-Maggs PH; Lillicrap D; Goudemand J; Berntorp E
    Haemophilia; 2008 Jul; 14 Suppl 3():56-61. PubMed ID: 18510523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined partial exon skipping and cryptic splice site activation as a new molecular mechanism for recessive type 1 von Willebrand disease.
    Gallinaro L; Sartorello F; Pontara E; Cattini MG; Bertomoro A; Bartoloni L; Pagnan A; Casonato A
    Thromb Haemost; 2006 Dec; 96(6):711-6. PubMed ID: 17139363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type 1 von Willebrand disease: application of emerging data to clinical practice.
    Collins PW; Cumming AM; Goodeve AC; Lillicrap D
    Haemophilia; 2008 Jul; 14(4):685-96. PubMed ID: 18510569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The application of genetics to inherited bleeding disorders.
    James P; Di Paola J
    Haemophilia; 2010 Jul; 16 Suppl 5():35-9. PubMed ID: 20590854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. von Willebrand disease: laboratory aspects of diagnosis and treatment.
    Favaloro EJ; Lillicrap D; Lazzari MA; Cattaneo M; Mazurier C; Woods A; Meschengieser S; Blanco A; Kempfer AC; Hubbard A; Chang A
    Haemophilia; 2004 Oct; 10 Suppl 4():164-8. PubMed ID: 15479392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis of von Willebrand disease in South Island, New Zealand.
    Rajagopal R; Smith MP
    Semin Thromb Hemost; 2011 Jul; 37(5):555-9. PubMed ID: 22102199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.
    De Meyer SF; Vandeputte N; Pareyn I; Petrus I; Lenting PJ; Chuah MK; VandenDriessche T; Deckmyn H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1621-6. PubMed ID: 18556568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology.
    Mazurier C; Goudemand J; Hilbert L; Caron C; Fressinaud E; Meyer D
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):337-47. PubMed ID: 11686103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.